Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUTEON ATLAS: 177Lu-TLX250 in Advanced ccRCC
NCT07870746Phase 2Not yet recruiting
- Sponsor
- Telix Pharmaceuticals Limited
- Start
- Oct 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 2 trial of 177-Lu-DOTA-cG250 in clear cell renal cell carcinoma (ccRCC), sponsored by Telix Pharmaceuticals Limited. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
177-Lu-DOTA-cG250
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT07870746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07870746.